Satish K. Garg spends much of his time researching Diabetes mellitus, Type 1 diabetes, Internal medicine, Endocrinology and Insulin. His Diabetes mellitus study combines topics from a wide range of disciplines, such as Anesthesia, Surgery and Risk factor. His study in Type 1 diabetes is interdisciplinary in nature, drawing from both Research design, Adverse effect, Randomized controlled trial and MEDLINE.
Satish K. Garg interconnects Diabetic retinopathy, Placebo, Retinopathy and Cardiology in the investigation of issues within Internal medicine. Satish K. Garg has researched Endocrinology in several fields, including Odds ratio and Coronary artery disease. The Hypoglycemia study combines topics in areas such as Glycated hemoglobin, Blood Glucose Self-Monitoring, Crossover study and Insulin pump.
Satish K. Garg focuses on Internal medicine, Diabetes mellitus, Endocrinology, Type 1 diabetes and Insulin. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Cardiology. His biological study spans a wide range of topics, including Surgery and Intensive care medicine.
The study incorporates disciplines such as Prospective cohort study and Calcium in addition to Endocrinology. The various areas that Satish K. Garg examines in his Type 1 diabetes study include Pregnancy and Preeclampsia. His Hypoglycemia research is multidisciplinary, incorporating perspectives in Glycated hemoglobin and Blood Glucose Self-Monitoring.
His scientific interests lie mostly in Internal medicine, Diabetes mellitus, Type 1 diabetes, Endocrinology and Insulin. His research in Internal medicine intersects with topics in Gastroenterology, Placebo and Semaglutide. Satish K. Garg focuses mostly in the field of Diabetes mellitus, narrowing it down to matters related to Intensive care medicine and, in some cases, MEDLINE.
His Type 1 diabetes research is multidisciplinary, relying on both Pregnancy, Preeclampsia and Glycemic. Satish K. Garg studied Endocrinology and Calcium that intersect with Phenylephrine. His Insulin study integrates concerns from other disciplines, such as Blood pressure and Family medicine.
The scientist’s investigation covers issues in Diabetes mellitus, Type 1 diabetes, Internal medicine, Glycemic and Hypoglycemia. His work carried out in the field of Diabetes mellitus brings together such families of science as Surgery, MEDLINE and Intensive care medicine. He combines subjects such as Young adult, Diabetic ketoacidosis, Clinical trial and Pediatrics with his study of Type 1 diabetes.
His Internal medicine research includes elements of Placebo and Endocrinology. His study in the field of Continuous glucose monitoring also crosses realms of Usability. His Hypoglycemia research incorporates themes from Glycated hemoglobin and Type 2 Diabetes Mellitus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino;Thomas Danne;Richard M. Bergenstal;Stephanie A. Amiel.
Diabetes Care (2019)
International Consensus on Use of Continuous Glucose Monitoring
Thomas Danne;Revital Nimri;Tadej Battelino;Richard M. Bergenstal.
Diabetes Care (2017)
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Nicole C Foster;Roy W Beck;Kellee M Miller;Mark A Clements.
Diabetes Technology & Therapeutics (2019)
Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial.
Satish Garg;Howard Zisser;Sherwyn Schwartz;Timothy Bailey.
Diabetes Care (2006)
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Richard M. Bergenstal;David C. K Klonoff;Satish K. Garg;Bruce W. Bode.
The New England Journal of Medicine (2013)
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
Robert E. Ratner;Irl B. Hirsch;James L. Neifing;Satish K. Garg.
Diabetes Care (2000)
Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
Richard M. Bergenstal;Satish Garg;Stuart A. Weinzimer;Bruce A. Buckingham.
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller;John Buse;Miles Fisher;Satish Garg.
The Lancet (2012)
Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.
Satish K Garg;Stuart A Weinzimer;William V Tamborlane;Bruce A Buckingham.
Diabetes Technology & Therapeutics (2017)
Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes.
H P Chase;S K Garg;G Marshall;C L Berg.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: